慢性淋巴细胞白血病与新型冠状病毒肺炎并存：流行病学、诊断及治疗挑战的全面综述
Concurrent chronic lymphocytic leukemia and COVID-19: A comprehensive review of epidemiological, diagnostic, and therapeutic challenges.
作者信息
Roosta Yousef, Behzadi Farhad, Askari Elham, Raeisi Mortaza, Danandeh Mehr Amin, Nouri-Vaskeh Masoud
机构信息
Department of Internal Medicine, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NTITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
出版信息
Leuk Res Rep. 2021;15:100239. doi: 10.1016/j.lrr.2021.100239. Epub 2021 Mar 16.
A comprehensive review of the literature on chronic lymphocytic leukemia (CLL) patients and recommendations regarding the evaluation and treatment of these patients was conducted. The overall prevalence of CLL and COVID-19 concurrence was found to be 0.6% (95%CI: 0.5% to 0.7%). Diagnostic interaction between CLL and COVID-19 remains a major challenge. Also, CLL patients have a lower rate of anti-SARS-CoV-2 IgG development. Evidences show the unacceptable therapeutic outcome in these patients. Although the CLL-COVID-19 occurrence is associated with adverse clinical consequences, no general and standard agreement has yet been presented for the management and treatment of this disease.
对慢性淋巴细胞白血病（CLL）患者的文献进行了全面综述，并就这些患者的评估和治疗提出了建议。发现CLL与COVID-19并发的总体患病率为0.6%（95%置信区间：0.5%至0.7%）。CLL与COVID-19之间的诊断相互作用仍然是一个重大挑战。此外，CLL患者抗SARS-CoV-2 IgG产生率较低。证据显示这些患者的治疗结果不理想。尽管CLL-COVID-19的发生与不良临床后果相关，但尚未就该疾病的管理和治疗达成普遍的标准共识。
Zotero 插件